Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Figures & data

Figure 1 Chemical structure of ceftolozane.

Figure 2 Chemical structure of tazobactam.

Table 1 Comparative activity of ceftolozane/tazobactam against selected U.S. clinical Gram-negative bacilli

MIC50 / MIC90 (mg/L)
Organism	Ceftolozane/tazobactam	Ceftazidime	Cefepime	Meropenem	Piperacillin/tazobactam
Pseudomonas aeruginosa	1/4	2/32	4/16	0.5/8	8/>64
Escherichia coli	0.25/0.5	0.12/2	≤0.5/4	≤0.06/≤0.06	2/8
Klebsiella spp.	0.25/2	0.12/32	≤0.5/8	≤0.06/≤0.06	4/>64
Enterobacter spp.	0.25/8	0.25/>32	≤0.5/2	≤0.06/≤0.06	2/64
Serratias spp.	0.5/1	0.12/0.5	≤0.5/≤0.5	≤0.06/≤0.06	2/4
Proteus mirabilis	0.5/0.5	0.06/0.06	≤0.5/≤0.5	≤0.06/≤0.06	≤0.5/1
Citrobacter spp.	0.25/8	0.25/>32	≤0.5/1	≤0.06/≤0.06	2/64

Notes: MIC breakpoint for ceftolozane/tazobactam has not been established. Data from Sader et al.²⁹

Abbreviations: MIC, minimum inhibitory concentration.

Table 2 Comparative activity of ceftolozane/tazobactam against selected European clinical Gram-negative bacilli

MIC50 / MIC90 (mg/L)
Organism	Ceftolozane/tazobactam	Ceftazidime	Cefepime	Meropenem	Piperacillin/tazobactam
Pseudomonas aeruginosa	1/4	2/>32	4/>16	0.5/>8	8/>64
Escherichia coli (non-ESBL)	0.25/0.25	0.12/0.25	≤0.5/≤0.5	≤0.06/≤0.06	2/8
Escherichia coli (ESBL)	0.5/4	0.16/> 32	>16/>16	≤0.06/≤0.06	8/>64
Klebsiella spp. (non-ESBL)	0.25/0.5	0.12/0.5	≤0.5/≤0.5	≤0.06/≤0.06	2/8
Klebsiella spp. (ESBL)	2/>32	32/>32	≤0.5/4	≤0.06/≤0.06	4/64
Enterobacter spp.	0.25/4	0.25/>32	≤0.5/4	≤0.06/≤0.06	4/64
Proteus mirabilis	0.5/1	0.06/0.25	0.5/≤0.5	≤0.06/0.12	≤0.5/1
Citrobacter spp.	0.25/8	0.25/>32	≤0.5/1	≤0.06/≤0.06	2/64

Notes: MIC breakpoint for ceftolozane/tazobactam has not been established. Data from Sader et al.³⁹

Abbreviations: MIC, minimum inhibitory concentration; ESBL, extended-spectrum β-lactamase.

SaderHSFlammRKStreitJMJonesRNActivity of novel antimicrobial ceftolozane/tazobactam tested against contemporary clinical strains from USA hospitals (2011)Abstracts: 52nd Interscience Conference on Antimicrobial Agents and ChemotherapyWashingtonAmerican Society for Microbiology2012

 Google Scholar

SaderHFarrellDJonesRNActivity of the novel antimicrobial CXA-201 tested against contemporary clinical strains from European hospitals (2012)Presented at: 22nd Annual Meeting of the European Congress of Clinical Microbiology (ECCMID)March 31–April 3, 2012London, UK

 Google Scholar